Zhejiang Shapuaisi Pharmaceutical (603168.SH) obtained the drug registration certificate for sodium bromfenac eye drops.
SAPAS (603168.SH) announcement, recently, the company has received approval from the National Medical Products Administration to issue bromfenac...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that recently, the company received the "Drug Registration Certificate" for the sodium bromfenac eye drops issued by the National Medical Products Administration. The sodium bromfenac eye drops approved this time are used for symptomatic treatment of inflammatory diseases of the external and anterior parts of the eye: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.
Related Articles
On June 23, LX Technology (02436) spent 579,800 Hong Kong dollars to repurchase 24,900 shares.
STAR CM (06698) spent HK$180,000 to repurchase 23,440 shares on June 23rd.
Overnight US stocks | Tech stocks continue to fall, with the Nasdaq plunging 2.2% and the Philadelphia Semiconductor Index dropping 7.8%.
On June 23, LX Technology (02436) spent 579,800 Hong Kong dollars to repurchase 24,900 shares.
STAR CM (06698) spent HK$180,000 to repurchase 23,440 shares on June 23rd.
Overnight US stocks | Tech stocks continue to fall, with the Nasdaq plunging 2.2% and the Philadelphia Semiconductor Index dropping 7.8%.
RECOMMEND
